Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
Open Access
- 11 June 2002
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (12) , 1843-1847
- https://doi.org/10.1038/sj.bjc.6600266
Abstract
To evaluate whether androgen deprivation impacts late rectal toxicity in patients with localised prostate carcinoma treated with three-dimensional conformal radiotherapy. One hundred and eighty-two consecutive patients treated with 3DCRT between 1995 and 1999 at our Institution and with at least 12 months follow-up were analysed. three-dimensional conformal radiotherapy consisted in 70–76 Gy delivered with a conformal 3-field arrangement to the prostate±seminal vesicles. As part of treatment, 117 patients (64%) received neo-adjuvant and concomitant androgen deprivation while 88 (48.4%) patients were continued on androgen deprivation at the end of three-dimensional conformal radiotherapy as well. Late rectal toxicity was graded according to the RTOG morbidity scoring scale. Median follow up is 25.8 (range: 12–70.2 months). The 2-year actuarial likelihood of grade 2–4 rectal toxicity was 21.8±3.2%. A multivariate analysis identified the use of adjuvant androgen deprivation (P=0.0196) along with the dose to the posterior wall of the rectum on the central axis (P=0.0055) and the grade of acute rectal toxicity (P=0.0172) as independent predictors of grade 2–4 late rectal toxicity. The 2-year estimates of grade 2–4 late rectal toxicity for patients receiving or not adjuvant hormonal treatment were 30.3±5.2% and 14.1±3.8%, respectively. Rectal tolerance is reduced in presence of adjuvant androgen deprivation.Keywords
This publication has 27 references indexed in Scilit:
- Correlation between dose-volume constraints and late rectum bleeding in patients treated for prostate cancer at dose between 70 and 76 GyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy aloneInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapyUrology, 1997
- Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology groupUrology, 1995
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology*Biology*Physics, 1995
- Neoadjuvant Hormonal Downsizing of Localized Carcinoma of the Prostate: Effects on the Volume of Normal Tissue IrradiationCancer Investigation, 1995
- Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long-term results of a prospective randomized studyInternational Journal of Radiation Oncology*Biology*Physics, 1988